Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
14h
Hosted on MSNVRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesVertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...
Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...
Yahoo News provides the latest updates on the spread of bird flu in the U.S., and its effect on rising egg prices and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results